| Code | CSB-RA761623MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to NC-318, targeting SIGLEC15 (Sialic Acid Binding Ig-like Lectin 15), a transmembrane protein that plays critical roles in immune regulation and bone remodeling. SIGLEC15 functions as an immune checkpoint molecule expressed on tumor-associated macrophages and myeloid cells, where it suppresses T cell activation and promotes an immunosuppressive tumor microenvironment. This target has emerged as particularly relevant in oncology research, as SIGLEC15 expression is largely absent in normal tissues but upregulated in various solid tumors, including non-small cell lung cancer, colorectal cancer, and head and neck cancers, making it an attractive therapeutic target distinct from PD-1/PD-L1 pathways.
NC-318 represents a pioneering anti-SIGLEC15 antibody that entered clinical development as a potential cancer immunotherapy agent. This biosimilar antibody provides researchers with a valuable tool for investigating SIGLEC15-mediated immune suppression, exploring combination immunotherapy strategies, and studying macrophage polarization in the tumor microenvironment. It supports investigations into novel immune checkpoint mechanisms and osteoclast biology.
There are currently no reviews for this product.